AVEO Pharmaceuticals, Inc.
Anti-NOTCH3 antibodies
Last updated:
Abstract:
Monoclonal antibodies that bind and inhibit activation of human Notch3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of Notch3.
Status:
Grant
Type:
Utility
Filling date:
8 Jan 2018
Issue date:
18 Aug 2020